Aberdeen Group plc Grows Stock Position in Krystal Biotech, Inc. $KRYS

Key Points

• Aberdeen Group plc increased its holdings in Krystal Biotech by 190.9%, owning approximately 0.38% of the company, valued at $14.9 million as reported in their recent SEC filing.
• Several institutional investors have made significant adjustments to their positions, with UBS AM boosting their stake by 173.8%, acquiring an additional 365,304 shares worth over $103 million.
• Analysts have mixed ratings for Krystal Biotech, with a current average rating of "Moderate Buy" and a price target of $209.00, while Bank of America slightly reduced its target price from $193.00 to $192.00.

Aberdeen Group plc grew its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 190.9% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 108,518 shares of the company's stock after purchasing an additional 71,217 shares during the quarter. Aberdeen Group plc owned approximately 0.38% of Krystal Biotech worth $14,917,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. EP Wealth Advisors LLC purchased a new stake in Krystal Biotech in the 1st quarter worth approximately $473,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Krystal Biotech by 173.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock worth $103,764,000 after acquiring an additional 365,304 shares in the last quarter. S Squared Technology LLC increased its holdings in Krystal Biotech by 2.1% in the 1st quarter. S Squared Technology LLC now owns 97,215 shares of the company's stock worth $17,528,000 after acquiring an additional 2,000 shares in the last quarter. Tempus Wealth Planning LLC purchased a new stake in Krystal Biotech in the 2nd quarter worth approximately $327,000. Finally, Fifth Third Bancorp increased its holdings in Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after acquiring an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on KRYS shares. Bank of America reduced their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Weiss Ratings reissued a "hold (c)" rating on shares of Krystal Biotech in a report on Wednesday, October 8th. HC Wainwright reissued a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a report on Monday, September 15th. Chardan Capital dropped their price target on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a research note on Friday, August 22nd. Finally, Citigroup restated a "neutral" rating and issued a $166.00 price target (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $209.00.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $188.05 on Wednesday. The company has a market capitalization of $5.44 billion, a P/E ratio of 38.22 and a beta of 0.64. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $207.84. The stock has a 50 day moving average price of $157.48 and a 200-day moving average price of $151.04.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. The firm had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. As a group, equities analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.